Skip to content
Screener

Altimmune ALT Q3 2025 earnings

Reported November 6, 2025 · Before market open

Revenue$5.0KBeat by $4.4K
EPS-$0.21Beat by $0.08
Revenue estimate$560.0
EPS estimate-$0.29

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$1.8K
EPS estimate-$0.14

Financials

Q3 2025

Income statement

See full
Revenue$5.0K0.0%
Operating income-$20.9M+15.8%
Net income-$19.0M+16.8%
EPS (diluted)-$0.21+34.4%

Balance sheet

See full
Cash & equivalents$61.3M+94.4%
Total debt$14.7M+729%
Total equity$185.6M+39.2%
Total assets$218.4M+47.7%

Cash flow

See full
Operating cash flow-$11.9M+56.1%
Free cash flow-$11.9M—

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$332.73M-23.8%
Enterprise value$286.14M-29.6%
P/S16,636.5×+8,245×

Profitability

See full
Operating margin-452,310%-4,915,478pp
Net margin-419,575%-4,318,884pp

Returns & leverage

See full
Return on equity-52.6%-11.5pp
Debt / equity0.1×+0.1×
Current ratio17.2×+0.3×

FAQ

When did Altimmune report Q3 2025 earnings?
Altimmune (ALT) reported Q3 2025 earnings on November 6, 2025 before market open.
What were Altimmune's Q3 2025 revenue and EPS?
Altimmune reported revenue of $5.0K and eps of $-0.21 for Q3 2025.
Did Altimmune beat estimates in Q3 2025?
Revenue beat the consensus estimate of $560.0 by $4.4K. EPS beat the consensus estimate of $-0.29 by $0.08.
How did Altimmune's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 0.0% from $5.0K a year earlier and eps grew 34.4% from $-0.32.
Where can I find Altimmune's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001326190-25-000067) and the 10-Q periodic report (0001326190-25-000064) directly on SEC EDGAR. The filing index links above go to sec.gov.